5317-32-8

Usage

Uses

Used in Pharmaceutical Industry:
1-Piperazinepropanol is used as a reactant for the preparation of biologically active molecules for various applications.
1-Piperazinepropanol is used as a reactant for the preparation of chloropyridazine piperazines, which serve as human rhinovirus (HRV-3) inhibitors. This application is crucial in the development of antiviral drugs to combat HRV-3 infections.
1-Piperazinepropanol is also used in the synthesis of arylbenzoylpyrrolidine derivatives, which exhibit Hsp90 inhibitory activity. Hsp90 (Heat shock protein 90) is a protein that plays a role in various cellular processes, and its inhibition can have therapeutic benefits in treating certain diseases.
Furthermore, 1-Piperazinepropanol is utilized in the preparation of pyrrolothienopyrazines, which act as novel serotonin-4 receptor antagonists. These compounds have potential applications in the treatment of various disorders related to serotonin regulation, such as gastrointestinal, cardiovascular, and central nervous system conditions.
Lastly, 1-Piperazinepropanol is used in the preparation of carbamate-functionalized 2,6-disubstituted N-(arylsulfonyl) piperidines. These compounds serve as conformationally restricted and orally active γ-secretase inhibitors, which are important in the development of drugs targeting Alzheimer's disease and other neurodegenerative disorders.

InChI:InChI=1/C7H16N2O/c1-2-7(10)9-5-3-8-4-6-9/h7-8,10H,2-6H2,1H3

Upstream product

• 110-85-0 piperazine 
• 107-18-6 allyl alcohol 
• 627-30-5 1-chloro-3-hydroxypropane 
• 7755-92-2 piperazine-1-carbaldehyde 
• 627-18-9 1-bromo-3-propanol 
• 7483-27-4 4-(3-hydroxypropyl)piperazinylcarboxylic acid ethyl ester 
• 627-32-7 1-iodopropan-3-ol 
• 210553-81-4 4-(3-hydroxypropyl)-1-piperazinecarboxaldehyde 
• 13173-24-5 N,N'-bis-allylpiperazine 

Downstream Products

• 5317-33-9 3-(4-methyl-1-piperazinyl)-1-propanol 
• 30297-78-0 3-(4-nitroso-piperazin-1-yl)-propan-1-ol 
• 101862-04-8 3-(4-cyanomethylpiperazin-1-yl)propan-1-ol 
• 90096-39-2 1-benzhydryl-4-(3-hydroxypropyl)piperazine 
• 1271943-25-9 3-{4-[3-(4-ethoxylphenoxy)propyl]piperazin-1-yl}-6-chloropyridazine 
• 1271943-27-1 3-{4-[3-(4-methylphenoxy)propyl]piperazin-1-yl}-6-chloropyridazine 
• 1271943-29-3 3-{4-[3-(4-ethylphenoxy)propyl]piperazin-1-yl}-6-chloropyridazine 
• 1271943-31-7 3-{4-[3-(4-isopropylphenoxy)propyl]piperazin-1-yl}-6-chloropyridazine 
• 1271943-33-9 4-{3-[4-(6-chloropyridazin-3-yl)piperazin-1-yl]propoxy}benzoic acid methyl ester 
• 124437-35-0 4-{3-[4-(6-chloropyridazin-3-yl)piperazin-1-yl]propoxy}benzoic acid ethyl ester 
• 1594853-44-7 3-(4-(4-(6-chloro-2-methoxyacridin-9-ylamino)phenyl)piperazin-1-yl)propan-1-ol 
• 16154-67-9 3-[4-(4-aminophenyl)-piperazin-1-yl]propan-1-ol 
• 16155-06-9 3-[4-(4-nitrophenyl)piperazin-1-yl]propan-1-ol 
• 1802929-43-6 6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)-8-[3-[4-(prop-2-enoyl)piperazin-1-yl]propyl]-7H,8H-pyrido[2,3-d]pyrimidin-7-one 

Relevant academic research and scientific papers

2-PHENYLIMIDAZO[4,5-B]PYRIDIN-7-AMINE DERIVATES USEFUL AS INHIBITORS OF MAMMALIAN TYROSINE KINASE ROR1 ACTIVITY

Compound of formula (I′) or (I′′) or a pharmaceutically acceptable salt thereof. The compound is an inhibitor of mammalian kinase enzyme activity, including ROR1 tyrosine kinase activity and may be used in the treatment of disorders associated with such activity.

Method for producing N-alkylpiperazine

PROBLEM TO BE SOLVED: To provide a method for producing N-alkyl piperazines in high yield by selectively alkylating one amino group.SOLUTION: In the method for producing N-alkyl piperazines, piperazines represented by general formula (1) are reacted with a specific alkylating agent in the presence of an acid. In the formula: R-Rare each independently a hydrogen atom, a methyl group, an ethyl group, a 3-8C linear alkyl group or the like, a hydroxyethyl group, a hydroxypropyl group, a dihydroxypropyl group, a methoxy group, an ethoxy group, a phenyl group, a benzyl group, a 2-phenylethyl group, or the like.

METHOD FOR PRODUCING N-MONOSUBSTITUTED PIPERAZINE

PROBLEM TO BE SOLVED: To provide a method for producing N-monosubstituted piperazine selectively with high productivity and high yields. SOLUTION: An electrophilic reagent and an alkali source are added to a solution comprising piperazine, which has been heated at 70-90°C, to make a reaction occur therebetween, so that an addition ratio of the electrophilic reagent to the piperazine is 0.2-0.7 mole and an addition amount rate of the electrophilic reagent exceeds an addition amount rate of the alkali source. SELECTED DRAWING: None COPYRIGHT: (C)2017,JPOandINPIT

Discovery of novel lead in the group of N-substituted piperazine ether derivatives with potential histamine H3 receptor activity

The search for novel lead from the group of various substituted N-piperazine ether derivatives was performed. Acyl- and pyridylpiperazine ethyl/propyl ethers were obtained via three different synthetic pathways. Affinity to histamine H3 receptor was established, as well as, for selected compounds, selectivity towards histamine H4R. Docking studies to the histamine H3R homology model strengthened the position of (4-(3-(4-(3-chlorobenzoyl) piperazin-1- yl)propoxy)phenyl)(cyclopropyl)methanone (compound 26) as a novel lead for further studies on histamine H3 receptor antagonist/inverse agonist.

PYRIDAZINE DERIVATIVES AND USE THEREOF AS MEDICAMENTS FOR TREATING MICRORNA VIRAL INFECTION

Disclosed are pyridazine derivatives represented by formula I or pharmaceutically acceptable salts or hydrates thereof, pharmaceutical compositions comprising the compounds, and the use of the compounds in preparing the medicaments for treating and/or preventing diseases or disorders associated with viral infections. The compounds represented by formula I have antiviral activity, especially anti-microRNA viral activity. Symbols in the compounds represented are described in the specification.

Arginase Inhibitors and Methods of Use Thereof

The present invention includes arginase enzyme inhibitors, compositions comprising these arginase inhibitors, and methods of treating or diagnosing conditions characterized either by abnormally high arginase activity or abnormally low nitric oxide levels in a mammal, comprising administering compositions of the invention to the mammal.

Pharmacophore-based design, synthesis, and biological evaluation of novel chloro-pyridazine piperazines as human rhinovirus (HRV-3) inhibitors

A series of chloro-pyridazine piperazines were developed based on the structure of human rhinovirus (HRV) capsid-binding inhibitors with proven activity using a pharmacophore model. A preliminary evaluation demonstrated potent activity against HRV-3 with low cytotoxicity. A docking analysis indicated that 8a could fit into, and form tight interactions (e.g., H-bonds, σ-π effect) with the active site in VP1.

Novel antagonists of serotonin-4 receptors: Synthesis and biological evaluation of pyrrolothienopyrazines

Based on the definition of a 5-HT4 receptor antagonist pharmacophore, a series of pyrrolo[1,2-a]thieno[3,2-e] and pyrrolo[1,2-a]thieno[2,3-e] pyrazine derivatives were designed, prepared, and evaluated to determine the properties necessary for high-affinity binding to 5-HT4 receptors. The compounds were synthesized by substituting the chlorine atom of the pyrazine ring with various N-alkyl-4-piperidinylmethanolates. They were evaluated in binding assays with [3H]GR113808 (1) as the 5-HT4 receptor radioligand. The affinity values (Ki or inhibition percentages) were affected by both the substituent on the aromatic ring and the substituent on the lateral piperidine chain. A methyl group on the tricyclic ring produced a marked increase in affinity while an N-propyl or N-butyl group gave compounds with nanomolar affinities. Among the most potent ligands, 34d was selected for further pharmacological studies and evaluated in vivo. This compound acts as an antagonist/weak partial agonist in COS-7 cells stably expressing the 5-HT4(a) receptor and is of great interest as a peripheral antinociceptive agent.

Cinnoline compounds

The invention relatest to compounds of the formula (I) wherein either any one of G1, G2, G3, G4 and G5 is nitrogen and the other four are —CH—, or G1, G2, G3, G4 and G5 are all —CH—; Z is —O—, —NH—, —S—, —CH2— or a direct bond; Z is linked to any one of G1, G2, G3 and G4 which is a free carbon atom; n is an integer from 0 to 5; any of the substitutents R1 may be attached at any free carbon atom of the indole, azaindole or indazole group; m is an integer from 0 to 3; Ra represents hydrogen; Rb represents hydrogen or another value as defined herein; R1 represents hydrogen, oxo, hydroxy, halogeno, C1-4alkyl, C1-4alkoxy, C1-4alkoxy, C1-4-alkyl, aminoC1-4alkyl, C1-3alkylaminoC1-4alkyl, di(C1-3alkyl)aminoC1-4alkyl, —C1-5alkyl(ring B) wherein ring B is selected from azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, N-methylpiperazinly, N-ethylpiperazinyl, morpholino and thiomorpholino; R2 represents hydrogen, hydroxy, halogeno, cyano, nitro, trifluoromethyl, C1-3alkyl, C1-3alkoxy, C1-3aklylsulphanyl, —NR3R4 (wherein R3 and R4, which may be the same or different, each represents hydrogen or C1-3alkyl), or R5X1— (wherein R5 and X1 are as defined herein) and salts thereof, processes for the preparation of such compounds, pharmaceutical compositions containing a compound of formula I or a pharmaceutically acceptable salt thereof as active ingredient and the use of a compound of formula I in the manufacture of medicament for the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals. The compounds of formula I and the pharmaceutically acceptable salts thereof inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis.

Application of piperazine-derived hydrazone linkers for alkylation of solid-phase immobilized ketones

The preparation and application of three new solid supports with piperazine-derived hydrazine anchoring groups are described. The supports were used for immobilization of ketones. The ketones: cyclohexanone, 4-tert-butylcyclohexanone, 3-pentanone and tropinone, which were bound to polymers in the form of their hydrazones, were deprotonated with LDA and alkylated with propyl iodide or benzyl bromide. The resulting alkylated products were cleaved off the solid support on treatment with trifluoroacetic acid in dichloromethane. Linkers with 6- and 3-carbon atom spacers gave better results than the simple N-aminopiperazine linker.